1234 Airport Road
463 articles about MiMedx
MiMedx Group, Inc. announced the filing of its 2018 Annual Report, which includes the Company's audited consolidated statements of operations, and stockholders' equity and cash flows for the years ended December 31, 2018 and 2017, which the Company did not previously file, and for the year ended December 31, 2016, which the Company has restated.
Seasoned Financial Expert to Assist in Transition of Financial Duties
MiMedx Group, Inc. announced that it expects to file its annual report on Form 10-K for the years ended December 31, 2018, 2017 and 2016 in early 2020.
The government said Petit and former Chief Operating Officer William Taylor engaged in a scheme to “fraudulently inflate” the revenue of MiMedx.
MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that Luis A. Aguilar has notified the Company of his resignation from the Board of Directors
The agreement provides that MiMedx will work in good faith to endeavor to complete the Restatement by December 16, 2019.
MiMedx Shareholder Group issued the following statement to fellow shareholders of MiMedx Group, Inc.:
Former Chairman and CEO Pete Petit of Mimedx Group, Inc. issued the following statement to fellow shareholders:
Company Urges Shareholders to Vote with the BLUE Card Online or By Phone
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS and Egan-Jones in Recommending MiMedx Shareholders Vote "For" All Three of the Company's Director Nominees
Glass Lewis and ISS Recommend Shareholders Vote AGAINST the Two Shareholder Proposals Submitted by Parker H. "Pete" Petit
Leading Independent Proxy Advisory Firms ISS and Egan-Jones Recommend That MiMedx Shareholders Vote the BLUE Card "FOR" All Three of the Company's Director Nominees
MiMedx Group, Inc. announced that leading proxy advisory firms Institutional Shareholder Services and Egan-Jones Proxy Services have recommended MiMedx shareholders vote "FOR" the Company's three director nominees – K. Todd Newton, Dr. Kathleen Behrens Wilsey and Timothy R. Wright – on the BLUE proxy card in connection with the Company's 2018 Annual Meeting of Shareholders to be held on June 17, 2019.
Mimedx Shareholder Group Urges Shareholders to Vote on the White Proxy Card for the 2018 Annual Meeting of Mimedx Group, Inc. on June 17, 2019
Mimedx Shareholder Group issued the following statement to fellow shareholders of Mimedx Group, Inc.
Company Urges Shareholders to Vote the BLUE Card Today
Website Provides Information About Upcoming 2018 Annual Meeting
Urges Shareholders to Vote "FOR" All the Board's Qualified Nominees on the BLUE Proxy Card
MiMedx Group, Inc. announced that the Company's board of directors has adopted a comprehensive plan to refresh the composition of the Board.
M. Kathleen Behrens Wilsey, the current chairwoman of the board at Sarepta Therapeutics, is slated to serve as the next chair of MiMedx.
Marks Important Step in Advancement of Company's Financial Restatement Process
Investigation Revealed Extensive Misconduct by Former Senior Management
MiMedx Group, Inc. announced that its Board of Directors has appointed Timothy R. Wright as Chief Executive Officer, effective May 13, 2019.